logo-loader
RNS
Apollon Formularies PLC

Apollon Formularies Plc - CANCER CELL KILLING RESULTS PUBLISHED IN THE PEER-REVIEWED ONLINE JOURNAL

February 20, 2024

Apollon Formularies Plc

("Apollon" or the "Company")

APOLLON FORMULARIES SUCCESSFUL CANCER CELL KILLING RESULTS PUBLISHED IN THE PEER-REVIEWED ONLINE JOURNAL OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (OJCAM)

- Apollon Formularies PLC (AQUS:APOL), an innovator in medical cancer research, proudly announces the peer-reviewed publication of their groundbreaking achievement in pre-clinical testing of Apollon's cancer therapeutic formulations.London, England

Utilising a strategic combination of medical cannabis and medicinal mushroom compounds, Apollon demonstrated successful cancer cell-killing results in prostate cancer, breast cancer, colon cancer, lung cancer, bladder cancer, and skin cancer through direct cytotoxicity and immune-targeted eradication of the cancer cells by T-cells and macrophages in blinded studies, performed by Bioensis Labs, as an independent third party testing facility.

The pioneering research, enriched by advanced AI-derived drug discovery techniques, has undergone rigorous peer review and has been formally published in the Online Journal of Complementary and Alternative Medicine (OJCAM).

Key Highlights of the Pre-Clinical Study:

The pre-clinical study, spearheaded by Dr. , former Professor and Chief of Clinical Chemistry at MD Anderson Cancer Center and Chief Science Officer of Apollon, delved into the synergistic potential of medical cannabis and medicinal mushrooms. The results showcase unprecedented efficacy in eradicating cancer cells, suggesting potential for use in the treatment of cancers of the prostate, breast, colon, lung, bladder, and skin.  The cytotoxicity of our formulations was established in blinded studies, performed by Bioensis Labs, as an independent third party. Herbert Fritsche

Dr. , Principal Investigator of the study, highlighted the scientific significance of the research, saying, "The successful cell-killing activity of our formulations in these various pre-clinical models, as published in the peer-reviewed Online Journal of Complementary and Alternative Medicine, demonstrate the potential of these formulations for developing innovative, low cost, non-toxic and highly effective cancer treatments."Herbert Fritsche

Dr. , a medical doctor and CEO of Apollon Formularies PLC, expressed his excitement about the transformative findings, stating, "This pre-clinical success is a significant leap forward in our mission to redefine cancer treatment. The promising outcomes across various cancer types, underscore Apollon's dedication to advancing patient-centric healthcare. We believe that our proprietary formulations, guided by AI-derived drug discovery techniques, hold great promise for the future of cancer therapies."Stephen Barnhill

This pre-clinical research marks a significant step forward in the development of effective and targeted natural cancer therapies. The complete pre-clinical study can be accessed in the peer-reviewed Online Journal of Complementary and Alternative Medicine (OJCAM).https://irispublishers.com/ojcam/pdf/OJCAM.MS.ID.000700.pdf

, Director of Product Manufacturing at Apollon Formularies PLC, underscored the practical implications of the results, stating, "Our proprietary formulations have now demonstrated success in  targeting malignant cells across numerous cancer types in pre-clinical testing. As we move forward, we are dedicated to translating these promising findings into tangible solutions for patients in need globally."Jeff Nagel

Apollon Formularies is enthusiastic about cultivating collaborative partnerships that epitomize adaptability and innovation. With a global outlook and a versatile array of capabilities, our company is poised to engage with potential strategic partners. Whether exploring in-and-out licensing agreements, engaging in collaborative research and development initiatives, forming international joint ventures, establishing strategic alliances, exploring import/export opportunities, or leveraging our academic affiliation and clinical trial capabilities, Apollon is resolute in its dedication to closely collaborating with like-minded partners. Together, we aim to unite efforts and bring state-of-the-art medicine to patients on a global scale.

For media inquiries or to initiate discussions about potential partnerships, please reach out to , Global COO for Apollon atStene Jacobs.stene@Apollon.org.uk

The directors of the Company accept responsibility for the contents of this announcement. 

For additional information, please visit  or contact:www.apollon.org.uk

Apollon Formularies                                                     

Tel:                                         +44 771 198 0221

Stene Jacobs                      stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)               

Tel:                                         +44 207 220 9795

Guy Miller                           gm@peterhousecapital.com

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.

1. AI-Derived Drug Discovery: Apollon Formularies PLC employs advanced AI
     techniques in drug discovery, leading to successful outcomes in killing
     cells from multiple cancer types.
1. Successful Pre-Clinical Cancer Cell Killing Results: The pre-clinical study
     demonstrated remarkable success in eradicating cancer cells in blinded
     studies, performed by Bioensis Labs, as an independent third party testing
     facility, with promising outcomes in prostate cancer, breast cancer, colon
     cancer, lung cancer, bladder cancer, and skin cancer
  2. Published in Peer-Reviewed Journal: The results have been peer-reviewed and
     officially published in the Online Journal of Complementary and Alternative
     Medicine (OJCAM), contributing to the scientific community's understanding
     of innovative natural cancer treatments.



NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read